tradingkey.logo
tradingkey.logo
Search

Immatics NV

IMTX
Add to Watchlist
9.950USD
+0.100+1.02%
Close 07/02, 13:00ETQuotes delayed by 15 min
1.21BMarket Cap
LossP/E TTM

TradingKey Stock Score of Immatics NV

Currency: USD Updated: 2026-07-01

Key Insights

Immatics NV's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 75 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.58.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Immatics NV's Score

Industry at a Glance

Industry Ranking
75 / 387
Overall Ranking
182 / 4564
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Immatics NV Highlights

StrengthsRisks
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
Growing
The company is in a growing phase, with the latest annual income totaling USD 56.02M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 56.02M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -13.03, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 101.84M shares, decreasing 14.61% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 8.17K shares of this stock.

Analyst Rating

Based on 11 analysts
Buy
Current Rating
18.578
Target Price
+83.39%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Immatics NV?

The TradingKey Stock Score provides a comprehensive assessment of Immatics NV based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Immatics NV’s performance and outlook.

How do we generate the financial health score of Immatics NV?

To generate the financial health score of Immatics NV, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Immatics NV's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Immatics NV.

How do we generate the company valuation score of Immatics NV?

To generate the company valuation score of Immatics NV, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Immatics NV’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Immatics NV’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Immatics NV.

How do we generate the earnings forecast score of Immatics NV?

To calculate the earnings forecast score of Immatics NV, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Immatics NV’s future.

How do we generate the price momentum score of Immatics NV?

When generating the price momentum score for Immatics NV, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Immatics NV’s prices. A higher score indicates a more stable short-term price trend for Immatics NV.

How do we generate the institutional confidence score of Immatics NV?

To generate the institutional confidence score of Immatics NV, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Immatics NV’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Immatics NV.

How do we generate the risk management score of Immatics NV?

To assess the risk management score of Immatics NV, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Immatics NV’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Immatics NV.